Skip to content
BioReperia logo — Accelerating drug discovery and predicting the best cancer t...

BioReperia

Accelerating drug discovery and predicting the best cancer treatment for you!

Founded 2015 Sweden Sweden 19 employees Series A Total: $8.00M Biopharma, Biotechnology +1

General Information

Company Name BioReperia
Founded Year 2015
Location Sweden Sweden
Employees 19
Industries Biopharma, Biotechnology, Life Sciences
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with BioReperia. To contact BioReperia, visit bioreperia.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BioReperia compare?

A PDF of BioReperia and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BioReperia soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BioReperia

BioReperia is a Swedish startup that is revolutionizing the fields of drug discovery and cancer treatment with its unique ZTX® platform (zebrafish tumor xenograft). The company's slogan, "Accelerating drug discovery and predicting the best cancer treatment for you!", encapsulates its mission to personalize and expedite cancer treatment. BioReperia's innovative approach allows for the rapid identification of the most effective drugs for individual cancer patients, significantly reducing the prediction time from 6 months to 5 days.

Founded in 2015, BioReperia is a leading contract research organization (CRO) in the biopharma and biotechnology industries. The company's groundbreaking platform offers in vivo data on tumor regression and metastasis inhibition within a week, providing a swift and accurate assessment of drug candidates. This agile and highly customizable toolbox for drug discovery holds the potential to enhance the success rate in clinical trials and improve cancer diagnosis.

Their most recent investment of kr8.00M came through a Series A investment on 22 May 2019, with Almi Invest and Hemex as the participating investors. This funding is a testament to the confidence that notable investors have in BioReperia's pioneering approach to revolutionize cancer treatment and drug discovery. With its headquarters in Sweden, BioReperia is poised to be a gamechanger in the biopharma and biotechnology landscape.

With lead products designed for precision medicine (ZTX®Predict) and drug discovery (ZTX®Oncoleads), BioReperia is on a mission to collaborate and make a significant impact in the fight against cancer. The company's commitment to saving time and financial resources while providing personalized and effective treatment options positions them as a key player in the future of cancer therapeutics.

For those looking to collaborate or learn more about BioReperia's innovative solutions, reaching out to the company at [email protected] is the first step toward potentially transforming the landscape of cancer treatment.

Business keywords: drug discovery, precision medicine, cancer treatment, zebrafish models, contract research organization, in vivo model, tumor xenograft, metastasis inhibition, immuno-therapies, patient-derived xenografts, Swedish biotech, oncology research, bioinformatics, biomedical innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A kr8.00M 2
Almi Invest, Hemex
22 May 2019
Seed Round Undisclosed 1
LEAD
01 Jun 2016

BioReperia Alternatives & Competitors

View All Alternatives
BioReperia vs
XenTech
XenTech France

Premium quality preclinical oncology CRO, pioneering the PDX technology for more than 16 years.

Seed
36 employees
Biotechnology, Health Care
BioReperia vs

A shift in cancer treatment methodology makes a world of difference.

Seed
16 employees
Biopharma, Biotechnology
BioReperia vs
Gordion Bioscience
Gordion Bioscience United States

MOTIVATED TO MAKE BETTER DRUGS - POWERED WITH TUMOR DATA - DELIVERED BY MACHINE LEARNING

7 employees
Biopharma, Biotechnology

FAQ About BioReperia

Accelerating drug discovery and predicting the best cancer treatment for you!
BioReperia was founded in 2015.
BioReperia is headquartered in Sweden.
BioReperia operates in Biopharma, Biotechnology and Life Sciences. Its work centres on drug discovery, precision medicine, cancer treatment and zebrafish models.
BioReperia has approximately 19 employees.
BioReperia has completed 2 funding rounds, raising a total of $8.00M. The latest funding stage is Series A.
Top alternatives and competitors to BioReperia include XenTech, Oniria Therapeutics, Gordion Bioscience, Soricimed Biopharma Inc., Viracta Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioReperia and XenTech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BioReperia, https://bouncewatch.com/company/bioreperia, updated 28 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout